Related Experiment Video
Updated: May 19, 2026
12:09
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine
Ellen S Vitetta1, Joan E Smallshaw, John Schindler
1Cancer Immunobiology Center, University of Texas Southwestern Medical School, Dallas, USA. ellen.vitetta@utsouthwestern.edu
Clinical and Vaccine Immunology : CVI
|August 24, 2012
Abstract:
There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.
